OncoMatch/Clinical Trials/NCT04621435
Imaging of Solid Tumors Using FAP-2286
Is NCT04621435 recruiting? Yes, currently enrolling (Jun 2026). This Phase 1 trial studies multiple treatments including Gallium-68 labelled (68Ga-) FAP-2286 and Copper-64 labeled (64Cu-) FAP-2286 for solid tumors, adult.
Treatment: Gallium-68 labelled (68Ga-) FAP-2286 · Copper-64 labeled (64Cu-) FAP-2286 — This is a multi-arm prospective trial that evaluates the ability of a novel imaging radiolabeled agents to detect metastatic cancer in participants with solid tumors using a gallium 68 (68Ga-) or copper 64 (64Cu-) FAP-2286 tracer. FAP-2286 is a peptidomimetic molecule that that binds to Fibroblast Activation Protein (FAP). FAP is a transmembrane protein expressed on cancer-associated fibroblasts, and has been shown to be present on a number of solid tumors.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Cancer type
Tumor Agnostic
Disease stage
Metastatic disease required
Metastatic Cancer
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- University of California, San Francisco · San Francisco, California
Showing up to 5 US sites.
See all sites on ClinicalTrials.gov →Frequently asked questions
Is NCT04621435 currently recruiting?
Yes, this trial is currently recruiting patients.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify